Super Speciosa Kratom Powders, Capsules, Extracts and Tinctures Review: It Publishes the Alkaloid Content — Which No Other Kratom Vendor We've Reviewed Does

Product Overview

Super Speciosa is one of the longest-established US kratom vendors, trading since 2016, selling powders, capsules, gummies, tablets, extracts, shots and tinctures across more than twenty strain varieties including green, red and white Maeng Da, Bali, Malay, Thai and Borneo.

Pricing runs from $19.99 to $49.99 per 100g of powder, with bulk up to 5kg at $499, capsules from $16 to $34.99 across 60 to 1,000 counts, gummies from $69.99, extracts and shots from $13.99 and tinctures from $33.99. It offers a 30-day satisfaction guarantee, same-day shipping and subscription discounts, and reports more than 100,000 customers with an on-site rating around 4.92.

On quality controls it does more than any kratom vendor we have looked at. It holds American Kratom Association GMP qualification, produces in what it describes as an FDA-registered, GMP-qualified facility, and tests every batch through third-party laboratories for purity, alkaloid concentration and microbial safety — with certificates accessible by scanning a QR code on the product label.

The single most important thing it does is publish mitragynine content. Select products disclose MIT percentages of 1.62% to 1.64%. Kratom alkaloid content varies substantially between strains, harvests and batches, and 'Maeng Da' is a marketing name rather than a specification — so a vendor telling you the actual percentage is giving you the one number that determines what a given amount of powder will do. When we reviewed another AKA GMP vendor recently, no potency figures were published at all.

Ingredients & Amounts

Publishing mitragynine percentages is genuinely useful and we want to give it full credit — at 1.62%, a 3-gram dose of powder contains roughly 49mg of mitragynine, which is a number you can actually reason about. That said, the disclosure appears on select products rather than universally, and the concentrated formats matter more than the leaf. Extracts, shots and tinctures raise 7-OH exposure sharply, and 7-OH is markedly more potent at mu-opioid receptors than mitragynine and than morphine. If you buy anything here, plain leaf powder or capsules are materially lower risk than any extract.

What the Manufacturer Claims

These claims are stronger than the category norm and mostly check out. Batch-level third-party testing with certificates reachable by QR code from the label is meaningfully better than a lab results page you have to hunt for, and testing that covers alkaloid concentration and microbial safety — not just identity — is the right panel. Two phrases still need translating. 'AKA GMP qualified' refers to the American Kratom Association's own good-manufacturing-practice programme: a genuine industry scheme with audit requirements, and better than nothing, but self-regulatory rather than governmental. And 'FDA-registered facility' means only that the facility has filed its details with the FDA — registration is not approval, and the FDA explicitly cautions against using it to imply otherwise. Notably, we did not find a statutory FDA disclaimer on the pages we reviewed, which is a gap given that competitors carry one.

What the Science Actually Supports

There is no FDA-approved use for kratom and no adequate controlled trial evidence supporting it for pain, anxiety, depression, energy or opioid withdrawal. Its use rests on tradition and self-report, not trial data.

The pharmacology is well characterised and is not gentle. Mitragynine is a partial agonist at mu-opioid receptors and 7-hydroxymitragynine a substantially more potent one — more potent than morphine at that receptor. The FDA describes the resulting effects in classic opioid terms: sedation, nausea and vomiting, constipation, physical dependence and withdrawal, and respiratory depression that can lead to death.

Dependence and withdrawal are well documented in regular users, with a syndrome resembling mild-to-moderate opioid withdrawal — irritability, muscle aches, insomnia, sweating, runny nose, gastrointestinal upset and craving.

Kratom-associated liver injury is a recognised adverse effect, typically appearing weeks into regular use with jaundice, itching, dark urine and abnormal liver enzymes. It usually resolves on stopping but has caused serious illness.

Seizures, tachycardia, hypertension, psychosis and neonatal abstinence syndrome in infants born to mothers using kratom have all been reported.

Contamination has been a repeated problem across the category, including a multistate salmonella outbreak traced to kratom products and FDA findings of heavy metals such as lead and nickel. That is precisely why batch testing of the kind Super Speciosa performs matters — and why buying untested kratom is a materially worse idea.

Limits of That Evidence

Directions, Warnings & Allergens

Pricing, Subscription, Refunds & Shipping

Pros & Cons

Who It May Be Best For

• •We do not have a group we would actively recommend this to
• •Adults already using kratom who have decided to continue and want the most rigorously tested and clearly labelled option available
• •Anyone in that position should choose plain leaf powder or capsules over extracts, use the published alkaloid figure to keep intake consistent rather than to escalate, avoid daily use, and tell their clinician

Who Should Avoid It

• •You live in Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Tennessee, Vermont or Wisconsin, where kratom is banned — or in a locality with its own ban
• •You take an SSRI, SNRI or other serotonergic medication, because of serotonin syndrome case reports
• •You take opioids, benzodiazepines, gabapentinoids, sleep medication, or drink alcohol regularly
• •You take any medication metabolised through CYP2D6 or CYP3A4 without checking with a pharmacist
• •You are pregnant, trying to conceive or breastfeeding
• •You have liver disease or abnormal liver function
• •You have a personal or family history of substance use disorder
• •You are considering kratom to manage opioid withdrawal — seek buprenorphine or methadone through a clinician instead
• •You are looking for treatment for pain, anxiety or depression, which have real evidence-based options
• •You are subject to workplace drug testing, as kratom alkaloids can be detected on expanded panels

Alternatives

Frequently Asked Questions

Our Take

Judged as a vendor, Super Speciosa is the best kratom operation we have reviewed, and one detail is why. It publishes mitragynine percentages. In a category where alkaloid content varies enormously between batches and strain names are pure marketing, telling customers that a product is 1.62% mitragynine is the difference between a knowable dose and a guess — and no other vendor we have looked at does it. Add batch-level third-party testing for purity, alkaloid concentration and microbial safety, certificates reachable by scanning the label, American Kratom Association GMP qualification and a track record back to 2016, and this is a company doing the hard parts properly.

That matters more than it might sound, because the category has genuine quality problems — a multistate salmonella outbreak and FDA findings of lead and nickel in tested samples. Buying tested kratom from a vendor that publishes its numbers is materially safer than buying untested kratom from a gas station.

But safer is not safe, and the vendor is not really the question. Kratom acts on mu-opioid receptors. It causes physical dependence and a withdrawal syndrome. It can cause liver injury. It can depress respiration, particularly alongside alcohol, benzodiazepines or opioids. It interacts with SSRIs and with a wide range of medicines through CYP2D6 and CYP3A4. There is no FDA-approved use, no established safe dose, and no controlled trial evidence for anything people take it for. It is illegal in nine states.

The extracts, shots and tinctures concern us most, as they did with the other kratom vendor we reviewed. Concentrating kratom raises 7-OH exposure, and in July 2026 the DEA announced its intent to schedule 7-OH above a threshold, with the FDA already issuing warning letters over such products.

We rate this 2.3 out of 5 — slightly above the other kratom vendor we have reviewed, entirely because of the alkaloid disclosure and QR-linked certificates. That is not a recommendation of kratom. It reflects a well-run company in a category we would steer almost every reader away from, and particularly readers of this site, many of whom take antidepressants that interact with it.

If you are dealing with pain, anxiety, low mood, fatigue or opioid dependence, all of those have real, supervised, evidence-based treatments — talk to a clinician about those instead. If you already use kratom and intend to continue, check your state's law, choose plain leaf over extracts, use the published alkaloid figure to keep your intake steady rather than to push it higher, avoid daily use, never mix it with other depressants, and tell your doctor.